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Abstract
Biomarkers have shown great promise over the past decade the process of drug 
development more effective and have become an integral part of diagnosis of 
diseases. Biosensors were integrated with biomarker detection and point-of-care 
detection for signal amplification, high specificity and sensitivity, rapid response 
time, low cost, simplicity and multi-analytical testing. In order to detect more 
sensitively, these particular biomarkers have been explored with the possibility of 
real-time measurements in order to develop simple and compact systems which 
can analyze complex specimens. Various biosensors including electrochemical 
biosensors have recently been developed based on disease-specific biomarkers in 
the diagnosis of cancer disease. The main objective of the book chapter is to review 
research with new materials/methods in electrochemical biosensing techniques to 
detection of breast cancer biomarkers and evaluating latest techniques for detection 
of important analytes in real samples. In this book chapter, the recent develop-
ment of electrochemical biosensors of breast cancer biomarkers will be reviewed. 
Furthermore, recent and future trend application of breast cancer biomarkers will 
be discussed.
Keywords: biomarkers, breast cancer, electrochemical immunosensors
1. Introduction
Cancer is considered a complex disease because several factors are involved the 
disease outbreak [1]. Breast cancer (BCa) is among the most common cancers in 
women, accounting for about 14% of deaths from cancer in women around the 
world. In both the developed and less developed world, breast cancer is the most 
common cancer in women. About 508,000 women worldwide are estimated to have 
died from breast cancer in 2011 [2].
One of the most important methods is the detection and analysis of cancer 
biomarkers. The development of cancer has the maximum potential for therapeutic 
intervention. Recent developments in molecular biology have made it clear that 
biomarkers of cancer play a major role in the treatment, prognosis and insight into 
cancer etiology. The National Cancer Institute describes a biomarker as a “biological 
molecule contained in blood, other body fluids or tissues that is a sign of a normal 
or abnormal process or disease or disorder.”
Cancer markers are one of the most valuable tools for early detection, diagnosis, 
treatment, progression tracking and evaluation of chemotherapy resistance. There 
are over 200 different cancer-related diseases impacting various parts of the human 
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body. Tumor markers are usually found at low levels in the absence of a tumor. After 
tumor formation, level changes and therefore cancer marker clinical tests must be 
fast, selective and sensitive sufficiently distinguish slight changes in marker levels 
in complex biological fluids.
Eventually, the extensive use of tumor markers in healthcare would rely on the 
identification of many highly selective and sensitive tumor markers. However, tra-
ditional immunoassays such as enzyme-linked immunosorbent assay (ELISA) have 
some drawbacks including time-consuming, extensive incubation procedures are 
performed for the antibody-antigen interaction to reach equilibrium and performed 
by highly skilled personnel using costly and sophisticated instruments.
1.1 Electrochemical immunosensors: definitions and methods
Over the past decade, a growing number of researchers have focused on devel-
oping fast and simple-to-use biosensor technology-based techniques to detect 
specific biomarkers. Under the proposed International Union of Pure and Applied 
Chemistry (IUPAC) concept, a biosensor combines two important components of 
the bioreceptor and the transducer component for target detection. The chemical 
biosensors have enticing instruments that can be measured to convert biological 
interactions into electric signals. Nevertheless, the conversion of biological signal to 
a measurable signal is difficult due to the limitations of the biological environment 
and the extremely low tumor marker rates in biological samples.
The development of effective biosensors with sensitivity and selectivity has thus 
gained significant emphasis not only in clinical medicine, as well as in basic medi-
cine and biomedical engineering. It is not surprising that due to their high potential 
in the bioassay region, the emphasis has been shifted to electrochemical biosensors 
as shown in Figure 1.
In addition to, they promote the reuse of molecules in biorecognition and 
prevent a time lapse among sample preparation and analysis. Moreover, biosensors 
have high potential to detect multiple biomarkers simultaneously. The use of elec-
trochemical biosensors is particularly noteworthy due to their low cost, usability, 
sensitivity, specificity and suitability to detect low levels of molecular biomarkers 
Figure 1. 
The construction of breast cancer biomarkers-based biosensors.
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using a range of available techniques like cyclic voltammetry (CV); differential 
pulse voltammetry (DPV); square-wave voltammetry (SWV) and electrochemical 
impedance spectroscopy (EIS). On the other hand, the electrochemical biosensors 
play a major role in moving towards simpler point-of-care (POC) research.
In this chapter, we addressed the molecular changes throughout cancer that have 
been developed and related biomarkers. Currently designed biosensor platforms 
and manufacturing methods to identify these biomarkers of cancer are discussed. 
Compared to the previous studies, this analysis highlights these biosensors analyti-
cal performance in terms of sensitivity, linear detection range and detection limit 
obtained with various manufacturing techniques.
2. Immunoassays with biomarkers for breast cancer
Cancer biomarkers are molecules in the presence of cancer in the body that are 
overexpressed. It can apply to a secreted enzyme triggered by a tumor or a specific 
body response to cancer. It is important to use a wide range of genomic, epigenetic, 
glycomic, proteomic and imaging biomarkers to recognize the point, prognosis, 
and epidemiology of cancer. Despite the fact that there are still multiple obstacles 
in turning the analysis of biomarkers into a therapeutic platform; several biomark-
ers dependent on genes and proteins have now been used. These biomarkers are 
reviewed in the following sections.
2.1 Carcinoembryonic antigen (CEA)
One of the first tumor antigens to be reported was carcinoembryonic antigen 
(CEA), defined in 1965. CEA is a glycoprotein of the immunoglobulin family found 
by radioimmunoassay or enzyme-linked immunosorbent assay in the serum of 
patients with cancer. A strong false positive rate in common communities and a 
poor test sensitivity and accuracy reduce the therapeutic benefit of CEA identifica-
tion. The elevated CEA level is not unique to breast cancer because CEA can be 
present in many various neoplasia forms. CEA is more prevalent in ductal than 
in lobular carcinomas in breast tumors. During the testing process, the FDA also 
identified CEA as an acceptable serum biomarker for colon cancer [3]. For detection 
of CEA, numerous electrochemical immunosensors have been developed [4–7].
Rizwan et al. [4] fabricated the nanocomposite of gold nanoparticles (AuNPs), 
carbon nano-onions (CNOs), single-walled carbon nanotubes (SWCNTs) and 
chitosan (CS) (AuNPs/CNOs/SWCNTs/CS) for the modification of GCE (glass 
carbon electrode) and development of highly sensitive label-free electrochemical 
immunosensor for the detection of carcinoembryonic antigen (CEA), clinical tumor 
marker using [Fe(CN)6]
3/4− as mediator solution. By using layer by layer fabrication 
of the immunosensors were observed using CV and SWV methods. When CEA 
antibody combines with CEA antigen, the formed immunocomplexes formed. The 
decrease in the electrical signals of the immunosensor has a linear relationship for 
the quantitative detection of CEA ranging from 100 fg mL−1 to 400 ng mL−1 with a 
low detection limit of 100 fg mL−1. Interestingly, a novel label-free electrochemical 
immunosensors [5] for detecting CEA based on gold nanoparticles (AuNPs) and Nile 
blue A (NB) hybridized electrochemically reduced graphene oxide (NB-ERGO) as 
shown in Figure 2. The NB-graphene oxide (NB-GO) composite was developed by 
the π-π interaction. The linear range of the proposed immunosensor was estimated at 
0.001–40 ng mL−1 under optimal conditions using DPV technique and the detection 
limit was estimated at 0.00045 ng mL−1 for CEA. In addition, a silver nanoparticle 
(AgNPs) decorated with thionine/infinite coordination polymers as sensing platforms 
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for detection of CEA. However, this type of glycoprotein associated with the develop-
ment of breast, ovary, pancreas, lung and colon cancer. The sensor showed a detection 
limit of 0.5 fg mL−1 and a wide linear range of 50 fg mL−1–100 ng mL−1 [6].
Additionally, simultaneous detection of carcinoembryonic antigen (CEA) and 
the carcinoma antigen 125 (CA125) constructed with the immunosensor contain-
ing vertical boron-doped graphene (VBG) and Boron-doped diamond (BDD) 
composite film by chemical vapor deposition method. These process characteristics 
add a wide unique surface area and strong electrocatalytic activity to the vertical BG 
(VBG)/BDD film resulting increase electroactive surface area. Hence, the Au-VBG/
BDD signal amplification device immunosensor demonstrated strong selectivity, 
specificity and excellent stability for the simultaneous identification of the CEA and 
CA125 at 0.5–100 pg mL–1 and 0.5–100 mU mL–1 concentrations, respectively, with 
detection limits of 0.15 pg mL–1 and 0.09 mU mL–1 respectively [7].
2.2 Cancer antigen 15-3 (CA15-3)
CA15.3 is among the most widely accepted common biomarkers linked with 
breast cancer and part of the mucins family with a glycoprotein [8]. The normal 
level of CA15-3 is under 30 U mL−1 in human serum [9]. The concentration of 
CA15-3 is also linked to the postoperative condition, recurrence rate and monitor-
ing of metastases of the patients. However, the serum level of this tumor marker is 
an important indicator for the early detection of breast cancer and the determina-
tion of disease severity. Several electrochemical biosensors focused on nanopar-
ticles have been designed for the identification of CA15-3. According to recent 
studies, we can explain that the design of biosensors includes a number of distinct 
nanostructures among the most commonly utilized signal enhancers.
Using sandwich based electrochemical was fabricated for detection of CA15-
3. According to this works, Qin and coworkers [10] used the sensitive sandwich 
Figure 2. 
Schematic of the fabrication of a sandwich-type immunosensor with a Au-VBG/BDD sensing electrode. 
Reprinted with permission from Ref. [5].
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electrochemiluminescence (ECL) immunosensors which were modified by graphene 
oxide-PEI carbon quantum dots (CQDs)-Au nanohybrid to detect CA15-3. Firstly, 
nanocomposite has been synthesized through dopamine and Ag+ redox reaction 
formed in Ag nanoparticles and polydopamine (AgNPs-PDA). The high-surface 
nanocomposite can provide an efficient substrate for initial antibody (Ab1) immo-
bilization. Carbon quantum dots (CQDs) are attached by amide bonds on polyethyl-
eneimine functionalized graphene oxide (PEI-GO). Gold nanoparticles are modified 
on CQDs-decorated PEI-GO substrates. Then, the secondary antibody (Ab2) was 
immobilized by AuNPs/CQDs-PEI-GO composite. According to this report, this 
ECL sensor showed good linear concentration range of CA15.3 from 0.005 to 500 U 
mL−1, with a relatively low detection limit of 0.0017 U mL−1. Further, an ultrasensi-
tive label-free electrochemical immunosensor configured with highly conductive 
dendritic Au@Pt core-shell nanocrystals (Au@Pt NCs) uniformly dispersed with 
ferrocene-grafted-chitosan (Fcg-CS) was prepared by Wang et al. [11]. Au@Pt NCs 
were developed using hexadecyl dimethyl benzyl ammonium chloride (HDBAC) as a 
growth-directing agent through a simple wet-chemical one-pot technique. According 
to this report, the proposed immunosensor had a low detection limit of 0.17 U mL−1 
and worked well over a linear range of 0.5–200 U mL−1. The technique designed for 
the immunosensor presents a feasible approach for clinical diagnostic applications.
In another study, Cobalt sulfides/graphene nanocomposite and AuNPs (CoS2-
GR-AuNPs) was used to detect CA15-3. In this composite, AuNPs act as the immo-
bilization site for binding of antibodies. CoS2-GR nanocomposite exhibits excellent 
electrocatalytic activity against catechol oxidation and also yields large surface area 
that enhances the amount of CA15-3 antibody immobilized as shown in Figure 3. 
The developed immunosensor showed a wide linear range of 0.1–150 U mL−1 
and a low detection limit of 0.03 U mL−1. The immunosensor demonstrated good 
precision, reliability, specificity and was successfully applied in serum samples for 
CA15-3 detection [12].
Figure 3. 
Formation strategies of Fc-CS and Au@Pt NCs, along with constructing a label-free electrochemical 
immunosensor. Reprinted with permission from Ref. [11].
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2.3 Human epidermal growth factor receptor 2 (HER2)
Anti HER2 is a monoclonal antibody (mAb) with molecular weight 185-kDa, 
that can bind HER2 protein and has been recognized as one of the biomarkers of 
breast cancer. HER2 is a receptor tyrosine kinase, a part of the cellular signaling 
pathways associated with the epidermal growth factor receptor (EGFR) family, 
which can complexes occurred in HER2 and alike proteins (such as erbB1, erbB3, 
and erbB4). Trastuzumab (Herceptin®), an antibody designed to treat breast 
cancer patients with a HER2 receptor, was the first genetically-guided medication 
authorized by the FDA [13], and included evaluations for its applicability before 
it could be used for both the diagnosis of HER2 positive gastric cancer and breast 
cancer [14]. HER2 overexpression in some breast cancer patients is often used as a 
main prognostic predictor and important treatment goals for the detection of breast 
cancer in adult females. The normal range in the blood of healthy women is between 
2 and 15 mg L−1. Since HER2 is linked with breast cancer, the development of highly 
sensitive biosensors to identify low levels of HER2 biomarkers is great importance.
For the detection of HER2, a disposable screen printed carbon electrode was 
modified with gold nanoparticles [15]. The gold nanoparticles allow rapid move-
ment of electrons and provide a biocompatible surface to immobilize small frag-
ments of antibodies in a directed manner, resulting in enhanced binding antigen 
performance. The proposed immunosensor showed a wide dynamic range of  
0.01–100 ng mL−1 with detection limit of 0.01 ng mL−1. The fabricated immu-
nosensor with HER2-avian single chain variable fragment (ScFv) has outstand-
ing durability with a retention rate of more than 95.6% up to 22 days. Recently, 
Shamsipur et al. [16] designed the label free immunosensor, functionalization of 
3-aminopropyltrimethoxysilane coated magnetite nanoparticles with antibody 
(antiHER2/APTMS-Fe3O4), as a platform bioconjugate (PB), and deposited on 
a bare GCE. However, the PB was covered with magnetic gold nanoparticles 
self-assembled by thiolated antibodies (antiHER2/Hyd@AuNPs-APTMS-Fe3O4) 
containing chemically reduced silver ions, as a bioconjugate (LB) label. Under 
optimized conditions, using DPV, the level of HER2 was determined obtained in the 
range of 5.0 × 10−4–50.0 ng mL−1 with a LOD of 2.0 × 10−5 ng mL−1.
Furthermore, an electrochemical sandwich-based immunosensor for HER2 was 
designed using a lead sulfide quantum dots anti-HER2 antibody as a label (Ab2-PbS 
QDs) [17]. The presence of amine and hydroxyl groups from secondary anti-HER2 
and coated PbS QDs are covalently linked together by carbonyldiimidazole (CDI) 
in the bioconjugation of PbS QDs. Using SWV signal, the proposed immunosen-
sor, the level of HER2 was determined the linear range from 1 to 100 ng mL−1 
with a limit of detection of 0.28 ng mL−1. Recently, Freitas et al. [18] developed a 
quantum dots (QDs) as electrochemical label for electrochemical immunosensing 
strategy established on in situ detection of HER2-ECD in human serum samples. By 
using the screen-printed electrode, core/shell CdSe@ZnS to provide immobiliza-
tion of bioreceptor functional groups as shown in Figure 4. The analytical per-
formance was tested in spiked human serum samples, demonstrating an excellent 
performance in a wide linear range (10–150 ng mL−1) with a limit of detection of 
2.1 ng mL−1.
2.4 MIRNAs
MIRNAs are a class of small non-coding RNA components that control the post-
transcription expression of target genes by either translational repression or mRNA 
degradation. Mature miRNAs are made up of β22 nucleotides and are generated 
through 70–100 nucleotide hairpin substrate molecules. The human genome has 
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been reported to be capable of encoding over 1000 miRNAs, which can control up 
to 60% of mammalian genes. MIRNA detection has produced a number of electro-
chemical sensors, which have been reviewed elsewhere.
In recent study, highly sensitive ultrasensitive electrochemical biosensor detec-
tion is of microRNA-222. In this works, the biosensor was fabricated as follows. 
The gold nanoparticles-modified graphene oxide (rGO/Au NPs) with capture 
probe (cDNA) through a thiolated group was immobilized. The modified electrode 
(cDNA/rGO/Au NPs/GCE) was linearly hybridized with microRNA-222 and signal 
probe, resulting in a sandwich structure of the modified electrode cDNA-microRNA 
signal probe on the surface. Under optimized conditions, using DPV technique, 
the biosensor of microRNA showed wide linear response range (0.5 fM to 70 nM) 
and a low limit of detection of 0.03 fM [19]. Further, a novel label free and simple 
electrochemical biosensors strategy was developed for detection of mRNA-21. From 
this research works, firstly confirmed with excellent ability of AuNPs superlattices 
for electron transport and tunable structures, a remarkable improvement was made 
in the immobilizing quantity of probe molecules on the electrode surface and a 
major improvement in the substratum’s electrical signal. Moreover, toluidine blue 
(TB) and micro-RNA interaction established with negatively charged backbone 
phosphate groups increasing electrostatic interaction. By using this technique, 
microRNA with a relatively low detection limit of 78 aM can be identified in a linear 
range from 100 aM to 1 nM. The proposed electrochemical nano biosensor could be 
clinically valuable in early breast cancer diagnosis through direct identification of 
serum microRNA-21 in real clinical samples without sample testing [20].
In addition, Azimzadeh et al. [21] developed a novel electrochemical nano 
biosensor for the detection of miRNA-155. From this works, this methodology 
based on thiolated probe-functional gold nanorods (GNRs) on a graphene oxide 
(GO) layer on a glass carbon electrode surface as shown in Figure 5. Nevertheless, 
the authors used Oracet Blue (OB) for the first time in the proposed electrochemical 
nano biosensor as an electroactive miRNA label. A novel intercalating label Oracet 
Blue, the reduction signals were measured using the method of differential pulse 
Figure 4. 
Representation of the immunosensor construction and detection strategy of biomarker HER2. Reprinted with 
permission from Ref. [19].
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voltammetry technique. This electrochemical nano biosensor method provided a 
linear range between 2.0 and 8.0 fM and a limit of detection of 0.6 fM. In addition, 
the versatility of the proposed nano biosensor has been demonstrated by direct 
detection of the miR-155 in plasma without the need for sample extraction and/or 
amplification, which can be applied in clinical applications such as early detection 
and/or as a predictor of drug response and prognostic trends in patients with breast 
cancer. Lastly, the proposed electrochemical nano biosensing method could also be 
used to detect any sequence of miRNAs, simply by changing the capture probe.
2.5 Cancer antigen 125 (CA125)
The cancer antigen 125 also known as mucin 16 (MUC 16) is a therapeutic 
tumor marker present in many ovarian cancer cells on the surface. However, some 
malignant diseases such as breast cancer, mesothelioma, non-Hodgkin’s lymphoma 
can lead to increased CA125 levels. Usually, the normal blood CA125 concentration 
is less than 35 U mL−1 (units per milliliter) [22, 23]. A number of electrochemical 
immunosensors for detection of CA125 have been developed so far.
Recent study, Fan et al. [24] developed paper-based electrochemical immu-
nosensor to detect cancer antigen 125 (CA125) by screen-printing method. The 
reduced nanocomposites of graphene oxide/thionine/gold (rGO/Thi/AuNPs) were 
compounded and coated for CA125 antibody (anti-CA125) immobilization and 
identification signal amplification on the paper electrode of the immunosensor. The 
principle of detection was based on the premise that the immunocomplex produced 
by the binding of CA125 antibody and antigen could reduce the current thionine 
reaction, which was corresponding to the corresponding CA125 antigen concentra-
tion. The results of the immunoassay demonstrate that the linear range of CA125 
was between 0.1 U mL−1 and 200 U mL−1 with a detection limit of 0.01 U mL−1.
Figure 5. 
(A) Molecular structure of the Oracet Blue molecule, (B) schematic illustration of the assembling and working 
procedure of the proposed electrochemical nanobiosensor for miR-155 detection. Reprinted with permission from 
Ref. [22].
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In addition, Ravalli and coworkers [25] developed the analytical performances 
of a label-free impedimetric immunosensor for the detection of tumor marker 
CA125 using modified screen-printed graphite electrode in gold nanoparticles. In 
this works the immunoassay is focused on a self-assembled monolayer (SAM) of 
electrodeposited gold nanostructures with corresponding monoclonal antibody 
immobilization on screen-printed graphite electrodes as shown in Figure 6. The 
development of immunosensor each steps are characterized using cyclic voltam-
metry (CV) and electrochemical impedance spectroscopy (EIS) techniques. The 
response of the immunosensor ranged linearly (r2 = 0.996) with antigen concentra-
tion varying from 0 to 100 U mL−1. The approximate detection limit was found to 
be 6.7 U mL−1. Also, the immunoassay was tested on serum samples, resulting in 
promising results for use with real samples.
Recently, Baradoke et al. [26] constructed Screen-printed carbon electrodes were 
electroplated with gold or platinum nanostructures and used as an antibody immo-
bilization platform for CA125. In this works, nanostructured surfaces have been used 
as a tool for the design of immunosensors and analyses in electrochemical kinetics 
such as antibody immobilization, electrode surface blocking and antigen binding. In 
addition, the detection of CA125 was demonstrated on the coated Au and Pt nano-
structured interfaces with a LOD of 419 ± 31 ng mL−1 and 386 ± 27 ng mL−1.
2.6 Breast cancer type 1 and 2 susceptibility proteins (BRCA1 and BRCA2)
In regards to breast cancer, some hereditary gene mutations were linked with 
the development of cancer, mainly identified with BRCA1 and BRCA2 tumor 
suppressor genes [27]. In specific, the BRCA1 gene encodes a protein of 1863 
Figure 6. 
Scheme of CA125 immunosensor developed: (A) electrodepositing of AuNPs on SPGE, (B) functionalization 
of gold nanoparticles with MUDA, (C) mixed SAM formation with MCH, (D) activation of COOH groups 
with EDAC/NHS and Ab-CA125 immobilization, (E) blocking step with rIgG, (F) Ab-Ag affinity reaction. 
Reprinted with permission from Ref. [26].
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amino acid implicated in genomic stability. Mutations in this gene are character-
ized as closely associated with and early onset of family breast cancer syndrome. 
These are also responsible for controlling and managing the checkpoints and cell 
division of the cell cycle. Mutations in the BRCA1 and BRCA2 genes are linked to 
increase of breast cancer and are essential for about 21–40% of hereditary cases of 
breast cancer [28]. BRCA1 protein expression was reported to be decreased in 30% 
of sporadic cases of breast cancer [29]. The extent of the BRCA1 protein reduc-
tion depends on the extent of the breast cancer and is inversely to the expression 
of BRCA2 protein used as a tool for the treatment of sporadic breast cancer [30]. 
Furthermore, BRCA2 can be used for breast cancer as both a prognostic and a 
screening biomarker.
Currently, Shahrokhian and Salimian [31] developed an ultrasensitive label-
free electrochemical DNA (E-DNA) sensor based on conducting polymer/reduced 
graphene-oxide platform has been developed for the detection of BRCA1 gene. An 
electrochemical technique was used as a simple and easy to control method for the 
electrochemical reduction of graphene oxide and also for the electropolimerization 
of the monomer of pyrrole 3 carboxylic acid. The signal produced from the E-DNA 
sensor uses CV, DPV and EIS methods to detect the redox probe’s electrochemical 
behavior. This sensor allows BRCA1 to be quantitatively determined in the linear 
range of 10 fM to 0.1 μM with a low detection limit as 3 fM. In addition, the modi-
fied electrode was effectively used in blood plasma samples to accurately determine 
the trace amounts of the DNA target.
Furthermore, recently developed novel immunoassay based on multiple poly-
mer signal amplification technique for BRCA1 protein recognition. The developed 
immunoassay processed by poly (dopamine-beta cyclodextrine-cetyl trimethylam-
monium bromide) doped by silver nanoparticles (P[DA-β-CD/CTAB])-AgNPs and 
functionalized mesoporous silica matrix (MCM-41-SO3H) produced on the glassy 
carbon electrode with a large surface area that has been designed to provide a new 
device for the immobilization of primary antibodies and outstanding conductivity. 
MCM-41-SO3H provides the appropriate volume of pores and functional groups to 
detect further horseradish peroxidase-labeled antibodies and improve conductiv-
ity to further amplify the electrochemical signal. The experimental immunoassay 
indicates adequate analytical efficiency for BRCA1 screening with a linear range of 
0.01565–10 pg mL−1 (DPV) and 0.625–20 pg mL−1 (SWV) and a low quantification 
value of 0.003 pg mL−1 [32].
In another study, label free DNA biosensor on a modified magnetic bar carbon 
paste electrode for BRCA1 mutation detection. In this research works, firstly, Fe3O4-
RGO nanoparticles were synthesized, accompanied by physical adsorption of the 
synthesized nanoparticles composite to the built magnetic bar carbon paste electrode 
(MBCPE) as shown in Figure 7. Using PANHS leads to decreasing electrode prepara-
tion, possessing an excellent selectivity for determination of BRCA1. However, the 
composite of the nanoparticles are linked with using 1-pyrene butyric acid-N-hydroxy 
succinimide ester (PANHS) as a detection of DNA sequence also (BRCA1 5382 insC 
mutation detection) strands were immobilized on the surface of the electrode for 
exact incubation time. By using EIS technique the linear range (1.0 × 10−18 mol L−1 
–1.0 × 10−8 mol L−1) and the low detection value of 2.8 × 10−19 mol L−1 [33].
2.7 Interleukin-6 and -8 (IL-6 and IL-8)
Interleukin-6 (IL-6) is a leukocyte-secreted 21 kDa glycoprotein, related 
to as both a pro- and an anti-inflammatory cytokine because it has roles in both 
directions. Interleukin (IL)-8 is an inflammatory chemokine contained in the 
subfamily C-X-clinically relevant rates of IL-6 in physiologically normal situations 
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have recently been recorded as 5–25 pg mL−1 and up to 1000 pg mL−1 in sepsis 
patients [34]. IL-8 is expressed by certain cell types, including activated monocytes 
and macrophages, a wide range of epithelial cells and fibroblasts [35].
For the detection of interleukin 1β in human serum and saliva, new impedi-
metric immunosensor was prepared using semi-conductive poly (2-thiophen-3-yl-
malonic acid) (P3-TMA) as matrix material for immobilization and anti-IL-1β 
antibody as a component for biorecognition. P3-TMA added a lot of antibody 
binding in the presence of carboxyl groups. EIS and CV techniques were used d 
to monitor the detection of IL-1β antigen concentration in the range of 0.01–3 pg 
mL−1 with the detection value of 3 fg mL−1 [36].
Using a similar principle, an impedimetric immunosensor for highly sensitive 
detection of IL-8 is in human serum and saliva samples. 6-phosphonohexanoic 
acid (PHA) was used to label the anti-IL-8 antibody. In addition, anti-IL8 antibody 
interaction to IL8 antigen was observed using SFI (single frequency impedance) 
technique as shown in Figure 8. EIS technique was applied for the interrogation of 
IL-6 level in the linear range of 0.02–3 pg mL−1 with a detection value of 6 pg mL−1 
and good stability (7 weeks) [37].
2.8 Vascular endothelial growth factor (VEGF)
Specific tyrosine kinase receptors divided into subtypes of VEGFR-1, VEGFR-
2, and VEGFR-3 are vascular endothelial growth factor receptors (VEGFRs). 
VEGFR-2 activates most angiogenic processes among the three forms. VEGFR-2 is 
an important biomarker for breast cancer with a blood level of >15 ng L−1 indicating 
the presence of tumors of the breast cancer [38].
For detection of VEGFR-2, a sandwich immunoassay was designed to detect 
VEGFR-2, by immobilizing anti-VEGFR-2 Ab1using chitosan/rGO/thionin-modi-
fied GCE as shown in Figure 9. An HRP-labeled Ab2 was used to identify antibody, 
Figure 7. 
Schematic representation of the modified electrochemical biosensor based on MBCPE/Fe3O4-RGO/PANHS 
platform. Reprinted with permission from Ref. [34].
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catalyzing thionine oxidation by H2O2. VEGFR-2 was quantified by DPV with a 
detection limit of 0.28 pM in the linear concentration range of 0.4–86.0 pM [39]. 
For its detection, VEGFR, sensitive label-free impedimetric sensor fabricated 
on molecular impressed polymer (MIP) as a biomimetic receptor coupled with 
screen-printed electrodes. Next, o-phenylenediamine (oPD) electropolymeriza-
tion was conducted on graphite-screen-printed electrodes in the presence of VEGF 
Figure 8. 
Schematic representation of the impedimetric immunosensor IL-8 detection. Reprinted with permission from 
Ref. [38].
Figure 9. 
Schematic representation of the electrochemical biosensing for VEGFR2 detection. Reprinted with permission 
from Ref. [40].
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molecules through cyclic voltammetry. The single-use MIP-based sensor demon-
strated good analytical efficiency for VEGF detection from 20 to 200 pg mL−1 with 
a detection limit of 0.08 pg mL−1 using with EIS technique [40].
2.9 Cluster differentiation 146 Ag (CD-146)
Cluster differentiation 146 Ag (CD-146) is a molecule of cell adhesion that belongs 
to the superfamily of immunoglobulins. It is identified as a progression marker for 
melanoma (melanoma adhesion molecule antigen) and breast cancer. The normal 
level of CD-146 in blood serum of healthy individuals is generally 309 μg L−1 [41].
For the identification of CD-146, a sandwich-based amperometric immunosensor 
was manufactured in which rGO-tetra ethylene pentaamine (TEPA) enhanced GCE 
antibody (Ab1) was immobilized as shown Figure 10. This improvement offered the 
electrode a large number of amino groups to improve the loading potential of anti-
bodies. The secondary Ab was controlled with colloidal sphere TiO2 and nanopar-
ticles Au/Pd and assay was conducted by calculating the amperometric reaction to 
electrocatalytic reduction of H2O2. However, the immunosensor displayed a wide 
linear range in 0.0050–20 ng mL−1, a low limit detection value of 1.6 pg mL−1 [42].
Furthermore, biomimetic mussel-inspired polydopamine coating photoelectro-
chemical biosensing chip was constructed to detect CD146. The CdS/TiO2-ITO chip 
was designed using the electrodeposition process to deposit CdS on the TiO2-ITO 
chip. In addition, the PDA (polydopamine), developed by DA (dopamine) self-
polymerization, was anchored on the CdS/TiO2-ITO (cadmium sulphide/titanium 
dioxide-indium tinoxide) chip surface through its strong adhesivity and specific 
interactions such as electrostatic attractions or covalent bindings. Also, without 
using external crosslinkers, PDA/CdS/TiO2-ITO chips could be used for direct 
immobilization of antibodies. By measuring the photocurrent responses to different 
concentrations of CD146, quantitative determination of CD146 was achieved based 
on this principle. The photocurrent decreased linearly from 1 pg mL−1 to 20 ng mL−1 
with an increase in CD146 concentration and a detection value of 0.3 pg mL−1 [43].
Figure 10. 
Schematic representation of the preparation of Au/Pd@TiO2-Ab2 (A) and immunosensor (B). Reprinted with 
permission from Ref. [43].
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2.10 Other important biomarkers
Biomarkers such as tenascin-C (TN-C); p53 tumor suppressor protein (p53); 
DNA methyltransferase (DNA-MTase); estrogen receptor (ER); matrix metal-
lopeptidase 9 (MMP-9); apurinic/apyrimidinic endonuclease 1 (APE1); mucin-like 
carcinoma-associated antigen (MCA); murine double minute 2 (MDM2); nuclear 
factor kappa B (NF-κB) are other important biomolecules that are known as tumor 
markers for breast cancer [44].
Tenascin-C is a large extracellular matrix protein newly expressed during tissue 
remodeling processes including angiogenesis, inflammation, and tumor growth. 
Tenascin-C is especially overexpressed in tumor tissues [45]. For the detection of TN-C 
a chemiluminescence (CL) based voltammetric immunosensor was prepared using car-
boxylated carbon nanoparticles (cCNPs) and conjugated with magnetic beads (MBs). In 
addition, an aptamer labeled with the CL reagent N-(4-aminobutyl)-N-ethylisoluminol 
was adsorbed to form labeled aptamer modified cCNPs-MBs on the surface of carboxy-
modified magnetic carbon nanoparticles. When the tenascin-C sample is applied, it will 
associate with the labeled aptamer to build a complex with the labeled aptamer. This 
complex is measured by CL whose amplitude is linearly linked to the tenascin C concen-
tration by 1 pM to 1 nM and the detection value as 0.4 pM respectively [46].
Tumor suppressor protein (p53) is an important transcription factor in regulat-
ing cellular responses to stress factors. Loss of p53 activity induces tumor activation 
and gene mutation, resulting in a conformational alteration in the p53 protein 
structure [47]. The level of p53 protein in serum samples from cancer patients varies 
from 0.52 ± 0.23 ng mL−1 to 1.03 ± 0.59 ng mL−1 [48]. Another, nanocomposite 
based ultrasensitive electrochemical immunosensor for p53 was designed using 
polycysteine/graphene quantum dots/gold nanoparticle. In this study, p53-antibody 
was immobilized on a green and biocompatible nanocomposite comprising l-cyste-
ine (P-Cys) as a conductive matrix and gold nanoparticles (GNPs) as a dual amplifi-
cation component of graphene quantum dots (GQDs). This approach facilitated the 
linear analysis of p53 in the range from 0.0244 to 0.369 pM (SWV technique) and 
0.195–50 pM (DPV technique) with a lower limit of 12.1 fM [49].
DNA methyltransferase (DNAMTase) is a widespread epigenetic alteration 
in both prokaryotes and eukaryotes and plays a crucial role in controlling gene 
expression, genomic stability and cell growth. Most tumors such as thyroid, liver, 
heart, prostate and breast cancer have over-expression of DNAMTase [50]. Further, 
DNAMTase was detected by label-free electrochemical biosensor for identification 
and inhibitor screening of methyltransferase activity based on graphene quantity 
and enzyme-catalyzed reaction. However, in this work, the modified HRP catalyzed 
the 3, 3′, 5, 5′-tetramethylbenzidine hydrogen peroxide-mediated oxidation result-
ing in an electrochemical signal production. The proposed biosensor achieved 
sensitivity detection of MTase activity within the range of 1–40 U mL−1 with a 
detection limit of 0.3 U mL−1 [51].
The biomarker of the estrogen receptor alpha (ERα) is a receptor and transcrip-
tion factor with nuclear hormones. It controls gene expression and inhibits the pro-
liferation and differentiation of cells in the target tissue. The occurrence of elevated 
ERα rates in the breast epithelium that implies an increased risk of breast cancer, 
indicating both the function of ERα in initiation and cancer progression [52]. For 
ERα detection, a electrochemical magneto immunosensing platform was developed 
taking an anti-human ERα antibodies modified SPCE. The antibody acquisition was 
immobilized on modified magnetic beads in carboxylic acid compounds, while the 
biotinylated antibody was labeled with a streptavidin-HRP conjugate. In addition, 
determining the target ERαprotein with a detection limit of 19 pg mL−1 evaluated 
the applicability of the integrated disposable magneto immunosensor [53].
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Matrix metalloproteinase 9 (MMP-9) is an extracellular 92 kDa protease belong-
ing to a family of endopeptidases dependent on zinc and calcium. There was an 
improvement in expression of MMP-9 in a number of different tumors relative to 
healthy subjects, with an overall positive association between tumor aggressive-
ness and activity levels of MMP-9 [54]. For detection of MMP-9, SERS (surface-
enhanced Raman scattering) nano-tags integrated magnetic-separation biosensor 
was designed with whole blood. The silica coated Ag SERS nano-tags built as labels 
were used to identify MMP-9 in unprocessed blood samples in a quick and accurate 
MSB immune sensor. The results showed the sensitive and reproducible response 
constructed in whole blood to the concentration of MMP-9 in the range up to 
100 ng mL−1 with a detection limit of 1 pg mL−1 [55].
Human apurinic/apyrimidinic endonuclease 1 (APE1) is an intracellular multi-
functional enzyme, also known as the redox impact factor 1. For detection of APE1, 
a novel electrochemical biosystem was designed by immobilizing antibody-APE1 
modified on gold electrode. The technique skillfully incorporates immunoassay 
through an intricate template of enzyme activity study. The APE1 biosensor detec-
tion limit is as low as 0.00518 U mL−1. The technique will monitor enzyme activity 
controlled by an APE1 inhibitor and its isozyme discrimination [56].
Mucin 1 (MUC1) protein is a membrane-associated glycoprotein containing 31 
amino acids in the hydrophobic domain, 69 amino acids in the cytoplasmic domain 
and 20 identical amino acids per repeat in the extracellular domain. MUC1 is also a 
well-known tumor marker present in a range of malignant tumors [57]. For detec-
tion of MUC1, carboxylic group of disposable electrochemical immunosensors rich 
in graphene oxide for the identification of biomarkers with methylene blue using 
with human serum samples. The authors investigated highly conductive surfaces of 
carboxylic group rich graphene oxide on screen-printed carbon electrodes in this 
process. The established immunosensor demonstrated good detection range (0.1–2 
U mL−1), for MUC1 with outstanding linearity with a detection limit of 0.04  
U mL−1 by using the differential pulse voltammetry (DPV) technique [58].
3. Future prospects and challenges
In recent years, the development of biosensors for biomarkers for breast cancer 
has received a lot of attention. However, the developments of biomarkers and the 
innovation of diagnostic tools for early detection of breast cancer are still in their 
early stages. While electrochemical immunoassays were very successful bio trans-
ducers, biomarkers established for breast cancer are needed to test their specificity, 
responsiveness and efficiency against the diagnostic standards created. The produc-
tion and progression of these advanced cancer screening systems will aid in the 
early stages of accelerated clinical cancer diagnoses. Nonetheless, proposed detec-
tion approaches for biomarker detection of cancer necessarily require standardiza-
tion of pre- and post-analytical protocols such as sample preparation, storage and 
optimization of experimental conditions for true validity of assays and more genu-
ine output of the biosensor produced. Although very low LODs have been obtained 
by electrochemical biosensors, they typically convey multi-step mark strategies that 
complicate the experimental activity. For future works, the development another 
problem is that owing to its low accuracy and reliability, few portable electrochemi-
cal instruments are in clinical usage. Therefore, robust biosensor-based POC 
devices are required of ultrasensitive electrochemical label-free methods will be a 
great potential. Researchers must train the electrochemical biosensor to solve their 
reliability problems with a significant number of clinical samples. The development 
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detection, as they can work in an invasively style. The approachable properties 
of electrochemical instruments improve the performance of cancer diagnostics 
and therapy monitoring. With further advancement and funding, these handheld 
instruments are anticipated to improve cancer diagnosis, rendering diagnostic find-
ings accessible in a matter of minutes at the patient bedside or practitioner’s office.
4. Conclusion
Novel electrochemical techniques for the detection of biomarkers of breast cancer 
have been established using the remarkable progress in nanotechnology and biosensor 
techniques. Effective electrochemical detection systems are combined with immunol-
ogy guidelines to host different antibody-complex reactions on the transducer surface 
and quantitatively identify the biomarkers. Current electrochemical biosensors, such 
as DNA or immunosensors, have extraordinary sensitivity that is important for early 
detection of cancer. The integration of electrochemical instruments with nano-scale 
materials provides a unique multiplexing mechanism for various cancer marker 
simultaneous measurements. However, before marketing the developed biosensors 
for actual clinical practices for the detection of biomarkers for breast cancer, impor-
tant gaps and approaches need to be addressed and implemented.
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